Laboratory Information Bulletins available to the public
Similar Posts
2023 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
This page contains the meeting materials for the Cardiovascular & Renal Drugs Advisory Committee meetings for 2023.Over-The-Counter Monograph Drug User Fee Program (OMUFA)
A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.FDA Information Session on Generic Drug Research Needs & Opportunities for FY 2026 – 01/21/2026
FDA is hosting a virtual Information Session on Generic Drug Research Needs & Opportunities for fiscal year (FY) 2026 on Wednesday, January 21, 2026.Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.Medtronic Announces Voluntary Recall of Select Newport™ HT70 and Newport™ HT70 Plus Ventilators and Certain Related Newport™ Service Parts
In May 2025, Medtronic issued a voluntary recall notification to global customers related to specific Newport™ HT70 and HT70 Plus ventilators and certain related Newport™ service parts. The FDA recently designated this voluntary action by Medtronic as a Class I recall.
With this recall, Medtronic iArterial Cannula Recall: Edwards Lifesciences Removes Arterial Cannula due to Risk of Wire Exposure
Edwards recalls arterial cannulae due to risk of wire exposure that may cause serious patient harm.